homovanillic acid has been researched along with Depression, Involutional in 31 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low gamma-aminobutyric acid (GABA) is implicated in both anxiety and depression pathophysiology." | 7.80 | Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid. ( Boldrini, M; Cooper, TB; Currier, D; Ellis, SP; Malone, KM; Mann, JJ; Oquendo, MA; Sullivan, G; Watson, KT; Xie, S, 2014) |
| "Low gamma-aminobutyric acid (GABA) is implicated in both anxiety and depression pathophysiology." | 3.80 | Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid. ( Boldrini, M; Cooper, TB; Currier, D; Ellis, SP; Malone, KM; Mann, JJ; Oquendo, MA; Sullivan, G; Watson, KT; Xie, S, 2014) |
| " We report, for the first time, the case of a man with depression experiencing hyperprolactinemia and galactopoiesis induced by ECT with the results of the plasma levels of homovanillic acid and 3-methoxy-4-hydroxyphenylglycol." | 3.78 | The case of a depressed man who exhibited hyperprolactinemia and galactopoiesis after electroconvulsive therapy. ( Atake, K; Katsuki, A; Nakamura, J; Tokutsu, Y; Umene-Nakano, W; Yoshimura, R, 2012) |
| "In this study, plasma obtained from monozygotic twin pairs discordant for schizophrenia (n = 10) or major affective disorder (n = 3) was assayed for epinephrine, norepinephrine, dihydroxyphenylacetic acid, homovanillic acid, adrencorticotropin hormone, and cortisol." | 3.71 | Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. ( Bonsall, R; Walder, DJ; Walker, EF, 2002) |
| "In the search for a biomarker for major depressive disorder (MDD), we used high-performance liquid chromatography to measure amino acids and related molecules in the cerebrospinal fluid (CSF) of 52 patients with MDD (42 depressed and 10 remitted; DSM-IV) and 54 matched controls." | 1.42 | Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder. ( Hattori, K; Higuchi, T; Hori, H; Kunugi, H; Matsumura, R; Matsuo, J; Motohashi, N; Noda, T; Ogawa, S; Ohashi, Y; Ota, M; Sasayama, D; Sato, H; Teraishi, T; Yokota, Y; Yoshida, S, 2015) |
| "Major depressive disorder is a prevalent disease, and current pharmacotherapy is considered to be inadequate." | 1.38 | Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. ( Bymaster, FP; Golembiowska, K; Kowalska, M, 2012) |
| "Mirtazapine treatment for 4 weeks significantly increased serum BDNF levels in the responders, whereas nonresponders showed significant decreases." | 1.38 | Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). ( Atake, K; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Iwata, N; Katsuki, A; Kishi, T; Nakamura, J; Umene-Nakano, W; Yoshimura, R, 2012) |
| "One hundred nine bipolar, 324 major depressive disorder, and 130 healthy volunteers were genotyped for the rs4131347 (-C8347G) promoter SNP." | 1.35 | No association between a TPH2 promoter polymorphism and mood disorders or monoamine turnover. ( Brent, D; Currier, D; Galfalvy, H; Greenhill, L; Huang, YY; Mann, JJ; Murphy, L; Oquendo, M, 2008) |
| "Both major depression and PTSD are thought to be associated with monoamine transmitter abnormalities." | 1.33 | Higher cerebrospinal fluid homovanillic acid levels in depressed patients with comorbid posttraumatic stress disorder. ( Burke, AK; Grunebaum, MF; Huang, YY; Li, S; Mann, JJ; Oquendo, MA; Sher, L; Zalsman, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 15 (48.39) | 29.6817 |
| 2010's | 13 (41.94) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, L | 1 |
| Yang, P | 1 |
| Yang, C | 1 |
| Yang, D | 2 |
| Wu, X | 1 |
| Cao, T | 1 |
| Zeng, C | 1 |
| Chen, Q | 1 |
| Zhang, S | 1 |
| Zhu, Z | 1 |
| Jiao, S | 1 |
| Cai, H | 1 |
| Ikenouchi, A | 1 |
| Okamoto, N | 1 |
| Igata, R | 1 |
| Natsuyama, T | 1 |
| Yoshimura, R | 6 |
| Ogawa, S | 2 |
| Tsuchimine, S | 1 |
| Kunugi, H | 2 |
| Horikoshi, S | 1 |
| Miura, I | 1 |
| Ichinose, M | 1 |
| Yamamoto, S | 1 |
| Ito, M | 1 |
| Watanabe, K | 1 |
| Kanno-Nozaki, K | 1 |
| Kaneko, H | 1 |
| Yabe, H | 1 |
| Sublette, ME | 1 |
| Galfalvy, HC | 1 |
| Hibbeln, JR | 1 |
| Keilp, JG | 1 |
| Malone, KM | 3 |
| Oquendo, MA | 5 |
| Mann, JJ | 7 |
| Watson, KT | 1 |
| Boldrini, M | 1 |
| Ellis, SP | 2 |
| Sullivan, G | 1 |
| Cooper, TB | 2 |
| Xie, S | 1 |
| Currier, D | 3 |
| Hattori, K | 1 |
| Sasayama, D | 1 |
| Yokota, Y | 1 |
| Matsumura, R | 1 |
| Matsuo, J | 1 |
| Ota, M | 1 |
| Hori, H | 3 |
| Teraishi, T | 1 |
| Yoshida, S | 1 |
| Noda, T | 1 |
| Ohashi, Y | 1 |
| Sato, H | 1 |
| Higuchi, T | 1 |
| Motohashi, N | 1 |
| Galfalvy, H | 2 |
| Huang, YY | 5 |
| Umene-Nakano, W | 3 |
| Ueda, N | 3 |
| Suzuki, A | 1 |
| Ikenouchi-Sugita, A | 2 |
| Otani, K | 1 |
| Nakamura, J | 5 |
| Pålhagen, S | 1 |
| Qi, H | 1 |
| Mårtensson, B | 1 |
| Wålinder, J | 1 |
| Granérus, AK | 1 |
| Svenningsson, P | 1 |
| Moreno, FA | 1 |
| Parkinson, D | 1 |
| Palmer, C | 1 |
| Castro, WL | 1 |
| Misiaszek, J | 1 |
| El Khoury, A | 1 |
| Mathé, AA | 2 |
| Wright, R | 1 |
| Delgado, PL | 1 |
| Cassidy, F | 1 |
| Weiner, RD | 1 |
| Carroll, BJ | 1 |
| Tokutsu, Y | 1 |
| Katsuki, A | 2 |
| Atake, K | 2 |
| Golembiowska, K | 1 |
| Kowalska, M | 1 |
| Bymaster, FP | 1 |
| Kishi, T | 1 |
| Hayashi, K | 1 |
| Iwata, N | 1 |
| Zheng, P | 1 |
| Wang, Y | 1 |
| Chen, L | 1 |
| Meng, H | 1 |
| Zhou, D | 1 |
| Zhong, J | 1 |
| Lei, Y | 1 |
| Melgiri, ND | 1 |
| Xie, P | 1 |
| Shinkai, K | 1 |
| Sher, L | 3 |
| Nikisch, G | 1 |
| Czernik, A | 1 |
| Eap, CB | 1 |
| Jiménez-Vasquez, P | 1 |
| Brawand-Amey, M | 1 |
| Baumann, P | 1 |
| Li, S | 1 |
| Burke, AK | 1 |
| Grunebaum, MF | 1 |
| Zalsman, G | 1 |
| Miniussi, C | 1 |
| Bonato, C | 1 |
| Bignotti, S | 1 |
| Gazzoli, A | 1 |
| Gennarelli, M | 1 |
| Pasqualetti, P | 1 |
| Tura, GB | 1 |
| Ventriglia, M | 1 |
| Rossini, PM | 1 |
| Salomon, RM | 1 |
| Kennedy, JS | 1 |
| Johnson, BW | 1 |
| Urbano Blackford, J | 1 |
| Schmidt, DE | 1 |
| Kwentus, J | 1 |
| Gwirtsman, HE | 1 |
| Gouda, JF | 1 |
| Shiavi, RG | 1 |
| Traskman-Bendz, L | 1 |
| Winchel, R | 1 |
| Fertuck, E | 1 |
| Stanley, BH | 1 |
| Meyer, JH | 1 |
| McNeely, HE | 1 |
| Sagrati, S | 1 |
| Boovariwala, A | 1 |
| Martin, K | 1 |
| Verhoeff, NP | 1 |
| Wilson, AA | 1 |
| Houle, S | 1 |
| Yukimasa, T | 1 |
| Murphy, L | 1 |
| Brent, D | 1 |
| Greenhill, L | 1 |
| Oquendo, M | 1 |
| Luyten, P | 1 |
| Blatt, SJ | 1 |
| Gerra, G | 1 |
| Leonardi, C | 1 |
| Cortese, E | 1 |
| Zaimovic, A | 1 |
| Dell'agnello, G | 1 |
| Manfredini, M | 1 |
| Somaini, L | 1 |
| Petracca, F | 1 |
| Caretti, V | 1 |
| Saracino, MA | 1 |
| Raggi, MA | 1 |
| Donnini, C | 1 |
| Cremniter, D | 1 |
| Jamain, S | 1 |
| Kollenbach, K | 1 |
| Alvarez, JC | 1 |
| Lecrubier, Y | 1 |
| Gilton, A | 1 |
| Jullien, P | 1 |
| Lesieur, P | 1 |
| Bonnet, F | 1 |
| Spreux-Varoquaux, O | 1 |
| Placidi, GP | 1 |
| Walker, EF | 1 |
| Bonsall, R | 1 |
| Walder, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of HS-10353 in Chinese Adult Subjects[NCT05195203] | Phase 1 | 96 participants (Actual) | Interventional | 2021-01-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for homovanillic acid and Depression, Involutional
| Article | Year |
|---|---|
Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: A meta-analysis of historic evidence.
Topics: Biomarkers; Depressive Disorder, Major; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxy | 2018 |
Looking back towards the future: is it time to change the DSM approach to psychiatric disorders? The case of depression.
Topics: Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Homovanillic Acid | 2007 |
7 trials available for homovanillic acid and Depression, Involutional
| Article | Year |
|---|---|
Low- and high-dose aripiprazole augmentation and plasma levels of homovanillic acid in major depressive disorder: A randomized, open-label study.
Topics: Adult; Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relation | 2019 |
Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Brain-Derived Neurotrophic Factor; Depressive Disorder, Maj | 2010 |
CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls.
Topics: Adult; Analysis of Variance; Case-Control Studies; Chromatography, High Pressure Liquid; Circadian R | 2010 |
Combined catecholamine and indoleamine depletion following response to ECT.
Topics: Adult; Aged; Catecholamines; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; El | 2010 |
Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Biomarkers; Depressive Disorder, Major; Dopam | 2002 |
Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression?
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Chromatography, High Pressure Liquid; Depress | 2005 |
Treatment enhances ultradian rhythms of CSF monoamine metabolites in patients with major depressive episodes.
Topics: Activity Cycles; Adult; Antidepressive Agents; Area Under Curve; Biogenic Monoamines; Depressive Dis | 2005 |
22 other studies available for homovanillic acid and Depression, Involutional
| Article | Year |
|---|---|
Disturbance of neurotransmitter metabolism in drug-naïve, first-episode major depressive disorder: a comparative study on adult and adolescent cohorts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adult; Biomarkers; Depressive Disorder, Major; Dopamine; | 2022 |
The Molecular Mechanism of Exercise for Treatment of Patients with Major Depression: A Preliminary Report on the Dynamics of Metabolites of Nitric Oxide and Catecholamines.
Topics: Catecholamines; Depression; Depressive Disorder, Major; Homovanillic Acid; Humans; Methoxyhydroxyphe | 2022 |
Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Fatty Acids, U | 2014 |
Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid.
Topics: Adult; Age Factors; Anxiety; Bipolar Disorder; Case-Control Studies; Chromatography, High Pressure L | 2014 |
Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder.
Topics: Adult; Amino Acids; Case-Control Studies; Demography; Depressive Disorder, Major; Ethanolamine; Fema | 2015 |
Increased risk of suicide attempt in mood disorders and TPH1 genotype.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Black or African American; Depressive Disorder, Major; Fe | 2009 |
Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression.
Topics: Aged; Analysis of Variance; Biogenic Monoamines; Brain-Derived Neurotrophic Factor; Corticosterone; | 2010 |
The case of a depressed man who exhibited hyperprolactinemia and galactopoiesis after electroconvulsive therapy.
Topics: Depressive Disorder, Major; Electroconvulsive Therapy; Ethylene Glycols; Homovanillic Acid; Humans; | 2012 |
Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Aza Co | 2012 |
Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD).
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Asian People; Brain-Derived Neurotrophic Fact | 2012 |
Identification and validation of urinary metabolite biomarkers for major depressive disorder.
Topics: Adult; Alanine; Biomarkers; Depressive Disorder, Major; Female; Formates; Homovanillic Acid; Humans; | 2013 |
Major depressive disorder and a past history of alcoholism.
Topics: Alcoholism; Comorbidity; Depressive Disorder, Major; Homovanillic Acid; Humans | 2003 |
Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response.
Topics: Adult; Chi-Square Distribution; Citalopram; Depressive Disorder, Major; Female; Homovanillic Acid; H | 2004 |
Higher cerebrospinal fluid homovanillic acid levels in depressed patients with comorbid posttraumatic stress disorder.
Topics: Adult; Chi-Square Distribution; Depressive Disorder, Major; Female; Homovanillic Acid; Humans; Linea | 2005 |
Lower cerebrospinal fluid homovanillic acid levels in depressed suicide attempters.
Topics: Adult; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dopamine; | 2006 |
Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study.
Topics: Adult; Age Factors; Carbon Radioisotopes; Corpus Striatum; Depressive Disorder, Major; Dopamine; Fem | 2006 |
[Therapeutic effectiveness of transcranial magnetic stimulation for intractable depressive disorders-- blood catecholamines and BDNF].
Topics: Adult; Aged; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Female; Homovanillic Aci | 2007 |
No association between a TPH2 promoter polymorphism and mood disorders or monoamine turnover.
Topics: Adult; Bipolar Disorder; Child; Child Abuse; Depressive Disorder, Major; Female; Genotype; Homovanil | 2008 |
Homovanillic acid (HVA) plasma levels inversely correlate with attention deficit-hyperactivity and childhood neglect measures in addicted patients.
Topics: Adult; Antisocial Personality Disorder; Anxiety; Attention Deficit Disorder with Hyperactivity; Chil | 2007 |
CSF 5-HIAA levels are lower in impulsive as compared to nonimpulsive violent suicide attempters and control subjects.
Topics: Adult; Aged; Anxiety Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Homovanilli | 1999 |
Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels.
Topics: Adult; Aggression; Depressive Disorder, Major; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 2001 |
Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adrenocorticotropic Hormone; Adult; Bipolar Disorder; Ca | 2002 |